Novel Approach Inspired by Barnacles Shows Promise in Treating Inflammatory Bowel Disease

Scientists exploring new avenues for alleviating symptoms of inflammatory bowel disease (IBD) have drawn inspiration from an unlikely source – barnacles.

IBD, encompassing conditions like Crohn’s disease and ulcerative colitis, is characterized by an immune system attack on the bowel, leading to inflammation. Symptoms include diarrhea, severe abdominal pain, weight loss, and bleeding in the gastrointestinal tract.

While anti-inflammatory medications like steroids can provide relief, persistent bleeding may necessitate the use of metal clips to seal wounds caused by inflammation. However, this method poses risks of infection and potential exacerbation of the wounds.

In a quest for a gentler alternative, researchers previously engineered bacteria to produce healing substances. However, these microbes are typically eliminated from the gut within a few days and require manual activation using drugs.

Building on this work, a team led by Bolin An at the Shenzhen Institute of Synthetic Biology in China has developed a strain of harmless Escherichia coli bacteria engineered to produce a wound-healing protein fragment in response to blood presence. Additionally, the bacteria produce specific “cement proteins” akin to those used by barnacles to attach to surfaces underwater, forming an anti-inflammatory seal to promote wound healing.

Experimental tests in mice induced with IBD-like symptoms showed promising results. Mice treated with the engineered bacteria exhibited significant weight regain and improved gut health compared to control groups. The bacteria, administered either through a gut tube or oral pill, remained in the gut and facilitated healing without adverse effects.

Shaji Sebastian, a researcher at Hull University in the UK, lauded the novel approach, highlighting its potential application in humans pending further studies. While the findings are encouraging, extensive testing in larger animals like pigs is planned to assess the bacteria’s longevity in the gut before clinical trials.

Although the road to clinical implementation may span up to a decade to ensure efficacy and safety, the development holds promise for revolutionizing IBD treatment and enhancing patient outcomes.